MRNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Moderna Inc (MRNA) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock is facing significant headwinds, including declining financial performance, insider and hedge fund selling, and a lack of strong positive catalysts. While there are some positive developments, such as the settlement removing litigation overhang and potential growth in oncology, the downside risks outweigh the potential upside in the near term. A hold strategy is recommended until clearer growth trends or stronger signals emerge.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), and the MACD is positive at 0.468, indicating a mildly bullish trend. However, RSI at 58.414 is neutral, and the stock is trading near its pivot level of 53.268, suggesting limited momentum. Key support is at 48.89, and resistance is at 57.646.
The $2.25 billion settlement removes a litigation overhang, providing some relief to investors.
Positive developments in oncology and the FDA's acceptance of the flu vaccine BLA filing could drive future growth.
Gross margin increased significantly YoY, showing operational efficiency improvements.
Financial performance is deteriorating, with revenue, net income, and EPS all declining significantly YoY in Q4
Hedge funds and insiders are selling aggressively, indicating a lack of confidence.
Analysts are largely cautious, with multiple underperform and neutral ratings, and price targets mostly below the current price.
In Q4 2025, revenue dropped 29.81% YoY to $678 million, net income fell 26.25% YoY to -$826 million, and EPS declined 26.99% YoY to -2.11. However, gross margin improved to 54.57%, up 25.51% YoY, indicating some operational efficiency gains.
Analysts are mixed to negative on Moderna. While some see the litigation settlement as a relief, others maintain cautious views with underperform and neutral ratings. Price targets range from $30 to $69, with most below the current price of $53.83.
